false2021Q20001549084--12-310.0666761P5DP5Dfive years, six months5.500015490842021-01-012021-06-30xbrli:shares00015490842021-07-26iso4217:USD00015490842021-06-3000015490842020-12-31iso4217:USDxbrli:shares00015490842021-04-012021-06-3000015490842020-04-012020-06-3000015490842020-01-012020-06-300001549084us-gaap:CommonStockMember2020-12-310001549084us-gaap:AdditionalPaidInCapitalMember2020-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001549084us-gaap:RetainedEarningsMember2020-12-310001549084us-gaap:RetainedEarningsMember2021-01-012021-03-3100015490842021-01-012021-03-310001549084us-gaap:CommonStockMember2021-01-012021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001549084us-gaap:CommonStockMember2021-03-310001549084us-gaap:AdditionalPaidInCapitalMember2021-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001549084us-gaap:RetainedEarningsMember2021-03-3100015490842021-03-310001549084us-gaap:RetainedEarningsMember2021-04-012021-06-300001549084us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001549084us-gaap:CommonStockMember2021-06-300001549084us-gaap:AdditionalPaidInCapitalMember2021-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001549084us-gaap:RetainedEarningsMember2021-06-300001549084us-gaap:CommonStockMember2019-12-310001549084us-gaap:AdditionalPaidInCapitalMember2019-12-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001549084us-gaap:RetainedEarningsMember2019-12-3100015490842019-12-310001549084us-gaap:RetainedEarningsMember2020-01-012020-03-3100015490842020-01-012020-03-310001549084us-gaap:CommonStockMember2020-01-012020-03-310001549084us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001549084us-gaap:CommonStockMember2020-03-310001549084us-gaap:AdditionalPaidInCapitalMember2020-03-310001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001549084us-gaap:RetainedEarningsMember2020-03-3100015490842020-03-310001549084us-gaap:RetainedEarningsMember2020-04-012020-06-300001549084us-gaap:CommonStockMember2020-04-012020-06-300001549084us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001549084us-gaap:CommonStockMember2020-06-300001549084us-gaap:AdditionalPaidInCapitalMember2020-06-300001549084us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001549084us-gaap:RetainedEarningsMember2020-06-3000015490842020-06-30xbrli:pure00015490842020-03-242020-03-240001549084ekso:EksoHealthMembersrt:MinimumMember2021-01-012021-06-300001549084srt:MaximumMemberekso:EksoHealthMember2021-01-012021-06-30ekso:customer0001549084us-gaap:AccountsReceivableMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001549084us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberekso:CustomerBMember2021-01-012021-06-3000015490842020-01-012020-12-310001549084us-gaap:AccountsReceivableMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001549084us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberekso:CustomerBMember2020-01-012020-12-310001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberekso:CustomerBMember2020-04-012020-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001549084us-gaap:RevenueFromContractWithCustomerMemberekso:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001549084us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001549084us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001549084us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001549084us-gaap:FairValueMeasurementsRecurringMember2021-06-300001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-06-300001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-06-300001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-06-300001549084us-gaap:FairValueMeasurementsRecurringMember2020-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001549084us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-12-310001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-01-012021-06-300001549084us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-06-3000015490842021-07-012021-06-3000015490842022-01-012021-06-3000015490842023-01-012021-06-300001549084srt:MinimumMember2021-01-012021-06-300001549084srt:MaximumMember2021-01-012021-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2021-04-012021-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2021-04-012021-06-300001549084us-gaap:ProductMember2021-04-012021-06-300001549084us-gaap:ServiceMemberekso:EksoHealthMember2021-04-012021-06-300001549084us-gaap:ServiceMemberekso:EksoWorksMember2021-04-012021-06-300001549084us-gaap:ServiceMember2021-04-012021-06-300001549084ekso:SubscriptionsMemberekso:EksoHealthMember2021-04-012021-06-300001549084ekso:SubscriptionsMemberekso:EksoWorksMember2021-04-012021-06-300001549084ekso:SubscriptionsMember2021-04-012021-06-300001549084ekso:EksoHealthMemberus-gaap:ProductAndServiceOtherMember2021-04-012021-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2021-04-012021-06-300001549084us-gaap:ProductAndServiceOtherMember2021-04-012021-06-300001549084ekso:EksoHealthMember2021-04-012021-06-300001549084ekso:EksoWorksMember2021-04-012021-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2021-01-012021-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2021-01-012021-06-300001549084us-gaap:ProductMember2021-01-012021-06-300001549084us-gaap:ServiceMemberekso:EksoHealthMember2021-01-012021-06-300001549084us-gaap:ServiceMemberekso:EksoWorksMember2021-01-012021-06-300001549084us-gaap:ServiceMember2021-01-012021-06-300001549084ekso:SubscriptionsMemberekso:EksoHealthMember2021-01-012021-06-300001549084ekso:SubscriptionsMemberekso:EksoWorksMember2021-01-012021-06-300001549084ekso:SubscriptionsMember2021-01-012021-06-300001549084ekso:EksoHealthMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2021-01-012021-06-300001549084us-gaap:ProductAndServiceOtherMember2021-01-012021-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2021-01-012021-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoWorksMember2021-01-012021-06-300001549084ekso:CollaborativeArrangementsMember2021-01-012021-06-300001549084ekso:EksoHealthMember2021-01-012021-06-300001549084ekso:EksoWorksMember2021-01-012021-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2020-04-012020-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2020-04-012020-06-300001549084us-gaap:ProductMember2020-04-012020-06-300001549084us-gaap:ServiceMemberekso:EksoHealthMember2020-04-012020-06-300001549084us-gaap:ServiceMemberekso:EksoWorksMember2020-04-012020-06-300001549084us-gaap:ServiceMember2020-04-012020-06-300001549084ekso:EksoHealthMemberekso:RentalsAndSubscriptionsMember2020-04-012020-06-300001549084ekso:EksoWorksMemberekso:RentalsAndSubscriptionsMember2020-04-012020-06-300001549084ekso:RentalsAndSubscriptionsMember2020-04-012020-06-300001549084ekso:EksoHealthMemberus-gaap:ProductAndServiceOtherMember2020-04-012020-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2020-04-012020-06-300001549084us-gaap:ProductAndServiceOtherMember2020-04-012020-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2020-04-012020-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoWorksMember2020-04-012020-06-300001549084ekso:CollaborativeArrangementsMember2020-04-012020-06-300001549084ekso:EksoHealthMember2020-04-012020-06-300001549084ekso:EksoWorksMember2020-04-012020-06-300001549084us-gaap:ProductMemberekso:EksoHealthMember2020-01-012020-06-300001549084us-gaap:ProductMemberekso:EksoWorksMember2020-01-012020-06-300001549084us-gaap:ProductMember2020-01-012020-06-300001549084us-gaap:ServiceMemberekso:EksoHealthMember2020-01-012020-06-300001549084us-gaap:ServiceMemberekso:EksoWorksMember2020-01-012020-06-300001549084us-gaap:ServiceMember2020-01-012020-06-300001549084ekso:EksoHealthMemberekso:RentalsAndSubscriptionsMember2020-01-012020-06-300001549084ekso:EksoWorksMemberekso:RentalsAndSubscriptionsMember2020-01-012020-06-300001549084ekso:RentalsAndSubscriptionsMember2020-01-012020-06-300001549084ekso:EksoHealthMemberus-gaap:ProductAndServiceOtherMember2020-01-012020-06-300001549084ekso:EksoWorksMemberus-gaap:ProductAndServiceOtherMember2020-01-012020-06-300001549084us-gaap:ProductAndServiceOtherMember2020-01-012020-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoHealthMember2020-01-012020-06-300001549084ekso:CollaborativeArrangementsMemberekso:EksoWorksMember2020-01-012020-06-300001549084ekso:CollaborativeArrangementsMember2020-01-012020-06-300001549084ekso:EksoHealthMember2020-01-012020-06-300001549084ekso:EksoWorksMember2020-01-012020-06-300001549084ekso:WarrantyMember2021-03-310001549084ekso:WarrantyMember2020-12-310001549084ekso:WarrantyMember2021-04-012021-06-300001549084ekso:WarrantyMember2020-01-012020-06-300001549084ekso:WarrantyMember2021-06-300001549084ekso:LoanAgreementMember2016-12-310001549084ekso:LoanAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2016-12-012016-12-310001549084ekso:LoanAgreementMember2020-04-292020-04-290001549084ekso:LoanAgreementMember2020-01-012020-12-310001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2020-08-310001549084ekso:PWBLoanAgreementMemberekso:TermLoanMemberus-gaap:PrimeRateMember2020-08-012020-08-300001549084ekso:LoanAgreementMember2021-01-012021-06-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2021-06-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2021-04-012021-06-300001549084ekso:PWBLoanAgreementMemberekso:TermLoanMember2021-01-012021-06-300001549084us-gaap:UnsecuredDebtMember2020-04-200001549084us-gaap:UnsecuredDebtMember2020-04-202020-04-200001549084us-gaap:UnsecuredDebtMember2021-06-282021-06-280001549084ekso:RichmondCaliforniaMember2021-06-300001549084ekso:RichmondCaliforniaMember2020-06-012020-06-300001549084ekso:HamburgGermanyMember2021-06-300001549084us-gaap:OverAllotmentOptionMemberekso:February2021OfferingMember2021-01-012021-02-280001549084us-gaap:OverAllotmentOptionMemberekso:February2021OfferingMember2021-02-280001549084ekso:February2021OfferingMember2021-01-012021-02-280001549084ekso:A2021WarrantsMember2021-01-012021-06-300001549084ekso:February2021OfferingMember2021-02-280001549084ekso:AtTheMarketOfferingMember2020-10-012020-10-290001549084ekso:AtTheMarketOfferingMember2020-10-290001549084ekso:AtTheMarketOfferingMember2021-01-012021-06-300001549084ekso:AtTheMarketOfferingMember2021-06-300001549084ekso:AtTheMarketOfferingMember2021-04-012021-06-300001549084ekso:AtTheMarketOfferingMemberus-gaap:CommonStockMember2021-01-012021-06-300001549084ekso:A2021WarrantsMember2021-06-300001549084ekso:A2021WarrantsMember2020-12-310001549084ekso:June2020InvestorWarrantsMember2021-06-300001549084ekso:June2020InvestorWarrantsMember2021-01-012021-06-300001549084ekso:June2020InvestorWarrantsMember2020-12-310001549084ekso:June2020PlacementAgentWarrantsMember2021-06-300001549084ekso:June2020PlacementAgentWarrantsMember2021-01-012021-06-300001549084ekso:June2020PlacementAgentWarrantsMember2020-12-310001549084ekso:December2019WarrantsMember2021-06-300001549084ekso:December2019WarrantsMember2021-01-012021-06-300001549084ekso:December2019WarrantsMember2020-12-310001549084ekso:December2019PlacementAgentWarrantsMember2021-06-300001549084ekso:December2019PlacementAgentWarrantsMember2021-01-012021-06-300001549084ekso:December2019PlacementAgentWarrantsMember2020-12-310001549084ekso:May2019WarrantsMember2021-06-300001549084ekso:May2019WarrantsMember2021-01-012021-06-300001549084ekso:May2019WarrantsMember2020-12-310001549084ekso:A2021WarrantsMember2021-01-012021-02-280001549084ekso:A2021WarrantsMember2021-02-280001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputSharePriceMember2021-02-110001549084us-gaap:MeasurementInputConversionPriceMemberekso:A2021WarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:A2021WarrantsMember2021-02-112021-02-110001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-02-110001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2021-02-110001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001549084ekso:A2021WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-02-110001549084ekso:June2020InvestorWarrantsMember2020-06-300001549084ekso:June2020InvestorWarrantsMember2020-01-012020-06-300001549084ekso:June2020InvestorWarrantsMember2020-06-012020-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020InvestorWarrantsMember2021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020InvestorWarrantsMember2020-12-310001549084us-gaap:MeasurementInputConversionPriceMemberekso:June2020InvestorWarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:June2020InvestorWarrantsMember2020-01-012020-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020InvestorWarrantsMember2021-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020InvestorWarrantsMember2020-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020InvestorWarrantsMember2021-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020InvestorWarrantsMember2020-12-310001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001549084ekso:June2020InvestorWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001549084ekso:June2020PlacementAgentWarrantsMember2020-06-012020-06-300001549084ekso:June2020PlacementAgentWarrantsMember2020-01-012020-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:June2020PlacementAgentWarrantsMember2020-12-310001549084us-gaap:MeasurementInputConversionPriceMemberekso:June2020PlacementAgentWarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:June2020PlacementAgentWarrantsMember2020-01-012020-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:June2020PlacementAgentWarrantsMember2020-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:June2020PlacementAgentWarrantsMember2020-12-310001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001549084ekso:June2020PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001549084ekso:December2019WarrantsMember2019-12-310001549084ekso:December2019WarrantsMember2019-12-012019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019WarrantsMember2020-12-310001549084us-gaap:MeasurementInputConversionPriceMemberekso:December2019WarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:December2019WarrantsMember2020-01-012020-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019WarrantsMember2020-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019WarrantsMember2020-12-310001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001549084ekso:December2019WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001549084ekso:December2019PlacementAgentWarrantsMember2019-12-310001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:December2019PlacementAgentWarrantsMember2020-12-310001549084us-gaap:MeasurementInputConversionPriceMemberekso:December2019PlacementAgentWarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:December2019PlacementAgentWarrantsMember2020-01-012020-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:December2019PlacementAgentWarrantsMember2020-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019PlacementAgentWarrantsMember2021-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:December2019PlacementAgentWarrantsMember2020-12-310001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2021-06-300001549084ekso:December2019PlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-12-310001549084ekso:May2019WarrantsMember2019-05-310001549084ekso:May2019WarrantsMember2020-06-300001549084ekso:DirectOfferingMemberus-gaap:CommonStockMemberekso:May2019WarrantsMember2020-06-300001549084ekso:June2020WarrantsMember2020-06-300001549084ekso:May2019WarrantsMember2020-01-012020-06-300001549084ekso:May2019WarrantsMember2019-05-012019-05-300001549084us-gaap:MeasurementInputSharePriceMemberekso:A2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputSharePriceMemberekso:A2019WarrantsMember2020-12-310001549084us-gaap:MeasurementInputConversionPriceMemberekso:A2019WarrantsMember2021-01-012021-06-300001549084us-gaap:MeasurementInputConversionPriceMemberekso:A2019WarrantsMember2020-01-012020-12-310001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:A2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputRiskFreeInterestRateMemberekso:A2019WarrantsMember2020-12-310001549084us-gaap:MeasurementInputExpectedTermMemberekso:A2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputExpectedTermMemberekso:A2019WarrantsMember2020-12-310001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:A2019WarrantsMember2021-06-300001549084us-gaap:MeasurementInputPriceVolatilityMemberekso:A2019WarrantsMember2020-12-310001549084ekso:June2020WarrantsMember2021-01-012021-06-300001549084ekso:EquityIncentivePlan2014Member2021-06-300001549084ekso:EquityIncentivePlan2014Member2020-12-310001549084ekso:EquityIncentivePlan2014Member2021-01-012021-06-300001549084ekso:EquityIncentivePlan2014Member2021-06-300001549084us-gaap:EmployeeStockOptionMember2021-06-300001549084us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001549084ekso:EquityIncentivePlan2014Member2020-01-012020-06-300001549084us-gaap:RestrictedStockUnitsRSUMember2021-06-300001549084us-gaap:RestrictedStockUnitsRSUMember2020-12-310001549084us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001549084us-gaap:SellingAndMarketingExpenseMember2021-04-012021-06-300001549084us-gaap:SellingAndMarketingExpenseMember2020-04-012020-06-300001549084us-gaap:SellingAndMarketingExpenseMember2021-01-012021-06-300001549084us-gaap:SellingAndMarketingExpenseMember2020-01-012020-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001549084us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2020-04-012020-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001549084us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-06-300001549084us-gaap:CommonStockMember2020-01-012020-06-3000015490842019-01-012019-12-310001549084us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-30ekso:license_agreement0001549084us-gaap:RoyaltyAgreementTermsMember2021-06-300001549084us-gaap:RoyaltyAgreementTermsMemberekso:SalesRevenueGoodsNetExcludingGovernmentSalesMember2021-01-012021-06-300001549084us-gaap:RoyaltyAgreementTermsMemberekso:LicenseRevenueMember2021-01-012021-06-300001549084us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001549084us-gaap:EmployeeStockOptionMember2020-04-012020-06-300001549084us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001549084us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001549084us-gaap:RestrictedStockMember2021-04-012021-06-300001549084us-gaap:RestrictedStockMember2020-04-012020-06-300001549084us-gaap:RestrictedStockMember2021-01-012021-06-300001549084us-gaap:RestrictedStockMember2020-01-012020-06-300001549084us-gaap:WarrantMember2021-04-012021-06-300001549084us-gaap:WarrantMember2020-04-012020-06-300001549084us-gaap:WarrantMember2021-01-012021-06-300001549084us-gaap:WarrantMember2020-01-012020-06-30ekso:segment0001549084country:US2021-04-012021-06-300001549084country:US2020-04-012020-06-300001549084country:US2021-01-012021-06-300001549084country:US2020-01-012020-06-300001549084ekso:AmericasOtherMember2021-04-012021-06-300001549084ekso:AmericasOtherMember2020-04-012020-06-300001549084ekso:AmericasOtherMember2021-01-012021-06-300001549084ekso:AmericasOtherMember2020-01-012020-06-300001549084srt:AmericasMember2021-04-012021-06-300001549084srt:AmericasMember2020-04-012020-06-300001549084srt:AmericasMember2021-01-012021-06-300001549084srt:AmericasMember2020-01-012020-06-300001549084country:DE2021-04-012021-06-300001549084country:DE2020-04-012020-06-300001549084country:DE2021-01-012021-06-300001549084country:DE2020-01-012020-06-300001549084country:BE2021-04-012021-06-300001549084country:BE2020-04-012020-06-300001549084country:BE2021-01-012021-06-300001549084country:BE2020-01-012020-06-300001549084ekso:EMEAOtherMember2021-04-012021-06-300001549084ekso:EMEAOtherMember2020-04-012020-06-300001549084ekso:EMEAOtherMember2021-01-012021-06-300001549084ekso:EMEAOtherMember2020-01-012020-06-300001549084us-gaap:EMEAMember2021-04-012021-06-300001549084us-gaap:EMEAMember2020-04-012020-06-300001549084us-gaap:EMEAMember2021-01-012021-06-300001549084us-gaap:EMEAMember2020-01-012020-06-300001549084srt:AsiaPacificMember2021-04-012021-06-300001549084srt:AsiaPacificMember2020-04-012020-06-300001549084srt:AsiaPacificMember2021-01-012021-06-300001549084srt:AsiaPacificMember2020-01-012020-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________ 
FORM 10-Q 
____________________________________________________________________________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______ 
Commission File Number: 001-37854 
____________________________________________________________________________________________ 
Ekso Bionics Holdings, Inc.

(Exact name of registrant as specified in its charter) 
____________________________________________________________________________________________
Nevada 99-0367049
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)
 
1414 Harbour Way SouthSuite 1201
RichmondCA
 94804
(Address of principal executive offices) (Zip Code)
 
(510) 984-1761
(Registrant’s telephone number, including area code)
________________________________
(Former name, former address, and former fiscal year, if changed since last report)
____________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Name of each exchange on which registered:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareEKSO
Nasdaq Capital Market


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x     No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
   
Non-accelerated filer Smaller reporting company
  
Emerging growth company 
 


Table of Contents


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act   
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No x
 
The number of shares of registrant’s common stock outstanding as of July 26, 2021 was 12,655,321.



Table of Contents
 Ekso Bionics Holdings, Inc.
 
Quarterly Report on Form 10-Q 

Table of Contents
  
 Page No.
  
   
   
 
   
 
   
 
   
 
   
   
   
   
  
   
   
   
 

3

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
 
Ekso Bionics Holdings, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
 
 June 30, 2021December 31, 2020
 (unaudited)(Note 2)
Assets  
Current assets:  
Cash$45,938 $12,862 
Accounts receivable, net of allowances of $90 and $42, respectively
2,756 3,224 
Inventories, net1,953 1,978 
Prepaid expenses and other current assets648 356 
Total current assets51,295 18,420 
Property and equipment, net1,059 1,172 
Right-of-use assets456 685 
Other assets163 320 
Total assets$52,973 $20,597 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$1,428 $1,501 
Accrued liabilities1,317 1,429 
Deferred revenues, current1,422 1,496 
Lease liabilities, current514 548 
Total current liabilities4,681 4,974 
Deferred revenues1,526 1,806 
Notes payable, net1,991 3,075 
Lease liabilities 233 
Warrant liabilities4,626 6,037 
Other non-current liabilities53 38 
Total liabilities12,877 16,163 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020
  
Common stock, $0.001 par value; 141,429 shares authorized; 12,655 and 8,349 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively
13 8 
Additional paid-in capital244,636 204,376 
Accumulated other comprehensive loss(507)(847)
Accumulated deficit(204,046)(199,103)
Total stockholders’ equity40,096 4,434 
Total liabilities and stockholders’ equity$52,973 $20,597 
 

The accompanying notes are an integral part of these condensed consolidated financial statements
4

Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
 
 Three Months Ended
June 30,
Six Months Ended
June 30,
 2021202020212020
Revenue$2,211 $2,264 $4,121 $3,731 
Cost of revenue919 1,005 1,594 1,835 
Gross profit1,292 1,259 2,527 1,896 
Operating expenses:
Sales and marketing1,787 1,712 3,580 4,232 
Research and development709 452 1,312 1,163 
General and administrative2,144 1,943 4,122 4,130 
Restructuring 244  244 
Total operating expenses4,640 4,351 9,014 9,769 
Loss from operations(3,348)(3,092)(6,487)(7,873)
Other income (expense), net:
Interest expense(27)(38)(53)(90)
Gain (loss) on revaluation of warrant liabilities875 (8,574)886 (6,055)
Warrant issuance expense (329) (329)
Gain on forgiveness of note payable1,099  1,099  
Other income (expense), net128 266 (388)46 
Total other income (expense), net2,075 (8,675)1,544 (6,428)
Net loss$(1,273)$(11,767)$(4,943)$(14,301)
Other comprehensive (loss) income(125)(193)340 (20)
Comprehensive loss$(1,398)$(11,960)$(4,603)$(14,321)
Net loss per share applicable to common shareholders, basic$(0.10)$(1.88)$(0.42)$(2.37)
Net loss per share applicable to common shareholders, diluted$(0.11)$(1.88)$(0.44)$(2.37)
Weighted average number of shares outstanding, basic12,655 6,261 11,709 6,032 
Weighted average number of shares outstanding, diluted12,737 6,261 11,839 6,032 
 
The accompanying notes are an integral part of these condensed consolidated financial statements
5

Table of Contents
Ekso Bionics Holdings, Inc.
Consolidated Statements of Stockholders’ Equity
(In thousands)
(Unaudited)
Convertible Preferred StockCommon StockAdditional Paid-in CapitalAccumulated Other Comprehensive
(Loss) Income
Accumulated DeficitTotal Stockholders’
 Equity
SharesAmountSharesAmount
Balance at December 31, 2020— $— 8,349 $8 $204,376 $(847)$(199,103)$4,434 
Net loss— — — — — — (3,670)(3,670)
Issuance of common stock under:
Equity financing, net— — 3,980 4 35,356 — — 35,360 
Exercise of warrants— — 300 1 3,877 — — 3,878 
Matching contribution to 401(k) plan— — 26 — 152 — — 152 
Stock-based compensation expense— — — — 356 — — 356 
Foreign currency translation adjustments— — — — — 465 — 465 
Balance at March 31, 2021— — 12,655 13 244,117 (382)(202,773)40,975 
Net loss— — — — — — (1,273)(1,273)
Stock-based compensation expense— — — — 519 — — 519 
Foreign currency translation adjustments— — — — — (125)— (125)
Balance at June 30, 2021— $— 12,655 $13 $244,636 $(507)$(204,046)$40,096 
6

Table of Contents
Convertible Preferred StockCommon StockAdditional Paid-in CapitalAccumulated Other Comprehensive IncomeAccumulated DeficitTotal Stockholders’ Equity
SharesAmountSharesAmount
Balance at December 31, 2019— $— 5,795 $6 $190,019 $50 $(183,278)$6,797 
Net loss— — — — — — (2,534)(2,534)
Issuance of common stock under:
Matching contribution to 401(k) plan— — 26 — 155 — — 155 
In lieu of cash compensation— — 9 — 50 — — 50 
Shares issued as a result of rounding due to reverse-stock split— — 13 — — — — — 
Stock-based compensation expense— — — — 587 — — 587 
Foreign currency translation adjustments— — — — — 173 — 173 
Balance at March 31, 2020— — 5,843 6 190,811 223 (185,812)5,228 
Net loss— — — — — — (11,767)(11,767)
Issuance of common stock under:— — — 
Equity financing, net— — 1,748 2 7,080 — — 7,082 
Exercise of warrants— — 223  1,436 — — 1,436 
Issuance of warrants— — — — (2,322)(2,322)
Stock-based compensation expense— — — — 508 — — 508 
Foreign currency translation adjustments— — — — — (193)— (193)
Balance at June 30, 2020— $— 7,814 $8 $197,513 $30 $(197,579)$(28)

The accompanying notes are an integral part of these condensed consolidated financial statements

7

Table of Contents
Ekso Bionics Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 Six Months Ended June 30,
 20212020
Operating activities:  
Net loss$(4,943)$(14,301)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization273 320 
Changes in allowance for doubtful accounts48 47 
Gain on forgiveness of note payable(1,099) 
(Gain) loss on revaluation of warrant liabilities(886)6,055 
Finance cost attributable to issuance of warrants 329 
Stock-based compensation expense875 1,095 
Amortization of debt discount and accretion of final payment fee2 23 
Gain on modification of operating lease liabilities (38)
Loss on investment of unconsolidated affiliate 66 
Common stock contribution to 401(k) plan107 99 
Unrealized loss on foreign currency transactions372 7 
Changes in operating assets and liabilities:
Accounts receivable420 1,420 
Inventories(136)194 
Prepaid expenses, right-of-use assets, and other assets current and noncurrent94 (84)
Accounts payable(73)(1)
Accrued, lease and other noncurrent liabilities(306)(746)
Deferred revenues(354)(230)
Net cash used in operating activities(5,606)(5,745)
Financing activities:
Proceeds from issuance of common stock and warrants, net37,295 7,082 
Principal payments on note payable (793)
Proceeds from issuance of long-term debt 1,086 
Proceeds from exercise of warrants1,417 785 
Net cash provided by financing activities38,712 8,160 
Effect of exchange rate changes on cash(30)(27)
Net increase in cash33,076 2,388 
Cash at beginning of period12,862 10,872 
Cash at end of period$45,938 $13,260 
Supplemental disclosure of cash flow activities
Cash paid for interest$46 $61 
Supplemental disclosure of non-cash activities
Fair value of warrants issued upon equity financing$1,936 $ 
Reclassification of warrant liability to equity upon exercise of warrants2,461  
Transfer of inventory from (to) property and equipment162 (89)
8

Table of Contents
Share issuance for common stock contribution to 401(k) plan152 155 
Share issuance in lieu of cash compensation 50 
 
The accompanying notes are an integral part of these condensed consolidated financial statements
9

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)

1.    Organization
 
Description of Business
 
Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology serves multiple markets and can be utilized both by able-bodied users and persons with physical disabilities. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait (acquired brain injury and spinal cord injury) to rehabilitate and to walk again, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005, the Company is headquartered in the San Francisco Bay area and listed on the Nasdaq Capital Market under the symbol “EKSO”.

All common stock share and per share amounts have been adjusted to reflect the one-for-fifteen reverse stock split effected on March 24, 2020. See Note 10, Capitalization and Equity Structure – Reverse Stock Split.
 
Liquidity and Going Concern
 
As of June 30, 2021, the Company had an accumulated deficit of $204,046.  Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of such technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. In the six months ended June 30, 2021, the Company used $5,606 of cash in its operations. Cash on hand as of June 30, 2021 was $45,938.

As described in Note 8, Notes payable, net, borrowings under the Company’s secured term loan agreement with Pacific Western Bank have a liquidity covenant requiring minimum cash on hand equivalent to the current outstanding principal balance. As of June 30, 2021, $2,000 of cash must remain as restricted. After considering cash restrictions, effective unrestricted cash as of June 30, 2021 is approximately $43,938. With this unrestricted cash balance, the Company believes that it currently has sufficient cash to fund its operations beyond the look forward period of one year from the issuance of these condensed consolidated financial statements.
 
2.    Basis of Presentation and Summary of Significant Accounting Policies and Estimates
 
Basis of Presentation and Consolidation
 
The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on February 25, 2021.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2020, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein.

The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or any future periods.
 
The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation.
10

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Use of Estimates
 
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.

Foreign Currency

The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss.

Inventory
 
Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first-in, first-out basis. Materials from vendors are received and recorded as raw material. Once the raw materials are incorporated in the fabrication of the product, the related value of the component is recorded as work in progress ("WIP"). Direct and indirect labor and applicable overhead costs are also allocated and recorded to WIP inventory. Finished goods are comprised of completed products that are ready for customer shipment. The Company periodically evaluates the carrying value of inventory on hand for potential excess amounts over sales and forecasted demand. Excess and obsolete inventories identified, if any, are recorded as an inventory impairment charge within the condensed consolidated statements of operations and comprehensive loss. The Company's estimate of write-downs for excess and obsolete inventory is based on a detailed analysis which includes on-hand inventory and purchase commitments in excess of forecasted demand. Subsequent disposals of inventories are recorded as a reduction of inventory.

Leases

At the inception of any lease arrangement, the Company determines whether the arrangement is or contains a lease under ASC 842 based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items, such as initial direct costs paid or incentives received.

Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.

Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations.
11

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)

The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, associated software (SmartAssist and VariableAssist), the sale and subscription of the EksoUE, the sale of accessories, and the sale of support and maintenance contracts (Ekso Care). In 2021, the Company focused on a customer subscription sales model while moving away from the rental sales model. Under the rental sales model, the Company offered customers a short term rental arrangement of its products to help bridge to a capital purchase since customers typically have challenges in obtaining approvals for capital expenditures. Subscription sales arrangements, however, circumvent the customer capital purchase process, is intended to renew annually, and provides a long term revenue stream.

Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, software and accessories. Ekso Care support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements. The separately priced Ekso Care contracts range from 12 to 48 months. The Company receives payment at the inception of the contract and recognizes revenue evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over 12 months.

The Company’s industrial device segment (EksoWorks) revenue is generated through the sale and subscription of the upper body exoskeletons (EksoVest and the recently introduced EVOTM) and the support arm (EksoZeroG). Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility. Revenue from industrial device subscriptions is recognized evenly over the contract term, typically 12 months.

The Company has exercised judgement to determine that straight-line is the most appropriate method of recognizing revenue for the aforementioned service and subscription contracts.

 
Refer to Note 6, Revenue Recognition for further information, including revenue disaggregated by source.

Going Concern
 
The Company assesses its ability to continue as a going concern at every interim and annual period in accordance with ASC 205-40. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
 
Concentration of Credit Risk and Other Risks and Uncertainties
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.

Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable as of June 30, 2021 and December 31, 2020. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.
 
At June 30, 2021, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable (11% and 20%), as compared with two customers at December 31, 2020 (10% and 13%).
 
12

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
During the three months ended June 30, 2021, the Company had one customer with sales of 10% or more of the Company’s total revenue (13%), as compared with two customers in the three months ended June 30, 2020 (11% and 13%).
 
During the six months ended June 30, 2021, the Company had one customer with sales of 10% or more of the Company’s total revenue (11%) as compared with no customers during the same period of 2020.
 
Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. The update will be effective for the Company in the first quarter of 2023. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this standard will have on its condensed consolidated financial statements and related disclosures.

In August 2020, the FASB issued ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the accounting for convertible instruments. ASU 2020-06 eliminates certain models that require separate accounting for embedded conversion features, in certain cases. Additionally, among other changes, the guidance eliminates certain of the conditions for equity classification for contracts in an entity’s own equity. The guidance also requires entities to use the if-converted method for all convertible instruments in the diluted earnings per share calculation and include the effect of share settlement for instruments that may be settled in cash or shares, except for certain liability-classified share-based payment awards. This guidance is effective for the Company beginning in the first quarter of 2022 and must be applied using either a modified or full retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact this guidance will have on its condensed consolidated financial statements.


3.    Accumulated Other Comprehensive Loss
 
The Company's accumulated other comprehensive loss consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive loss presented on the condensed consolidated balance sheets for the six months ended June 30, 2021 and 2020, are reflected in the table below net of tax:
 Six Months Ended June 30,
20212020
Balance at beginning of period$(847)$50 
Net unrealized gain on foreign currency translation340 (20)
Balance at end of period$(507)$30 
 
4.    Fair Value Measurement
 
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value which are the following:
 
Level 1—Quoted prices in active markets for identical assets or liabilities. The Company considers a market to be active when transactions for the asset occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
13

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The valuation of Level 3 investments requires the use of significant management judgments or estimation.

The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement, on a recurring basis are as follows:
 TotalLevel 1Level 2Level 3
June 30, 2021    
Liabilities    
Warrant liabilities$4,626 $ $ $4,626 
December 31, 2020
Liabilities
Warrant liabilities$6,037 $ $ $6,037 
 
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities for the period ended June 30, 2021, which were measured at fair value on a recurring basis:
 Warrant Liability
Balance at December 31, 2020$6,037 
Initial fair value of warrants in connection with 2021 financing1,936 
Gain on revaluation of warrants issued in connection with the February 2021, June 2020, December 2019 and May 2019 financings(886)
Reclassification of warrant liability to equity upon exercise of warrants(2,461)
Balance at June 30, 2021$4,626 
 
Refer to Note 10. Capitalization and Equity Structure – Warrants for additional information regarding the valuation of warrants.
 
5.    Inventories, net
 
Inventories consisted of the following:
 June 30, 2021December 31, 2020
Raw materials$1,441 $1,724 
Work in progress211 18 
Finished goods301 236 
Inventories, net$1,953 $1,978 

14

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
6.    Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which when capable of being distinct, are accounted for as separate performance obligations. Revenue recognition is evaluated based on the following five steps: (i) identification of the contract with the customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.
 
For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not directly observable, judgment is made to estimate the selling price based on market conditions and entity-specific factors including cost plus analyses, features and functionality of the product and/or services, the geography of the Company’s customers, and type of the Company’s markets. Any discounts or other reductions to the transaction price are allocated proportionately to all performance obligations within the multiple-element arrangement. The Company periodically validates the stand-alone selling price for performance obligations by evaluating whether changes in the key assumptions used to determine the stand-alone selling prices will have a significant effect on the allocation of transaction price between multiple performance obligations.

The Company exercised judgement to determine that a product returns reserve was not required as historical returns activity have not been material.
 
Contract Balances
 
Timing of revenue recognition may differ from the timing of invoicing to customers and receipt of payment. For the sale of its products, the Company generally recognizes revenue at a point in time through the ship-and-bill performance obligations. For the subscription of its products, the Company generally recognizes revenue over the subscription term commencing upon the completion of customer training. For service agreements, the Company generally invoices customers at the beginning of the coverage period and records revenue related to the billed amounts over time, equivalent to the coverage period of the maintenance and support contract.
 
Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts (Ekso Care), but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service.
 
Deferred revenue consisted of the following:
June 30, 2021December 31, 2020
Deferred extended maintenance and support$2,568 $2,902 
Deferred royalties280 282 
Deferred device and advances100 118 
Total deferred revenues2,948 3,302 
Less current portion(1,422)(1,496)
Deferred revenues, non-current$1,526 $1,806 
 
Deferred revenue activity consisted of the following for the six months ended June 30, 2021:
Beginning balance$3,302 
Deferral of revenue548 
Recognition of deferred revenue(902)
Ending balance$2,948 
 
15

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
As of June 30, 2021, the Company’s deferred revenue was $2,948. The Company expects to recognize approximately $839 of the deferred revenue during the remainder of 2021, $1,011 in 2022, and $1,098 thereafter.

In addition to deferred revenue, the Company has non-cancellable backlog of $1,348 related to its contracts for subscription units with its customers. These subscription contracts typically have 12-month terms and subscription income is recognized on a straight-line basis over the lease term.
 
As of June 30, 2021 and December 31, 2020, accounts receivable, net of allowance for doubtful accounts, were $2,756 and $3,224, respectively, and are included in current assets on the Company’s condensed consolidated balance sheets.
 
The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 to 90 days.
 
Disaggregation of revenue
 
The following table disaggregates the Company’s revenue by major source for the three months ended June 30, 2021:
 EksoHealthEksoWorksTotal
Device revenue$1,090 $288 $1,378 
Service and support447  447 
Subscriptions185 52 237 
Parts and other140 9 149 
 $1,862 $349 $2,211 

The following table disaggregates the Company’s revenue by major source for the six months ended June 30, 2021:
 EksoHealthEksoWorksTotal
Device revenue$2,109 $386 $2,495 
Service and support935  935 
Subscriptions337 122 459 
Parts and other194 24 218 
Collaborative arrangements14  14 
 $3,589 $532 $4,121 

The following table disaggregates the Company’s revenue by major source for the three months ended June 30, 2020:
16

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
 EksoHealthEksoWorksTotal
Device revenue$1,382 $161 $1,543 
Service and support333  333 
Rentals and subscriptions197 3 200 
Parts and other69 14 83 
Collaborative arrangements105  105 
 $2,086 $178 $2,264 

The following table disaggregates the Company’s revenue by major source for the six months ended June 30, 2020:
 EksoHealthEksoWorksTotal
Device revenue$1,688 $416 $2,104 
Service and support715  715 
Rentals and subscriptions478 3 481 
Parts and other223 36 259 
Collaborative arrangements172  172 
 $3,276 $455 $3,731 

7.    Accrued Liabilities
 
Accrued liabilities consisted of the following:
June 30, 2021December 31, 2020
Salaries, benefits and related expenses$1,144 $1,194 
Device warranty146 188 
Other27 47 
Total$1,317 $1,429 
 
The current portion of the device warranty liability is classified as a component of accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three and six months ended June 30, 2021 is as follows:
Three Months EndedSix Months Ended
June 30, 2021
Balance at beginning of period$195 $226 
Additions for estimated future costs 71 117 
Incurred costs(67)(144)
Balance at end of period$199 $199 
Balance as of June 30, 2021
Current portion$146 
Long-term portion53 
Total$199 
 
8.    Notes Payable, net
 
17

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
WAB and PWB Term Loans

WAB Term Loan

In December 2016, the Company entered into a loan agreement with Western Alliance Bank (the "WAB loan") and received a loan in the principal amount of $7,000 that bore interest on the outstanding daily balance at a floating per annum rate equal to the 30-day U.S. LIBOR plus 5.41%. The Company was required to pay accrued interest on the WAB loan on the first day of each month through and including January 1, 2018. Commencing on February 1, 2018, the Company was required to make equal monthly payments of principal, together with accrued and unpaid interest maturing on January 1, 2021. On April 29, 2020 the Company entered into a second amendment to the WAB loan to defer principal payments for three months beginning in May 2020, with adjustments when the principal payments resumed on August 1, 2020. During the three-month deferral period the Company was required to make interest only payments.

The final payment fee, debt issuance costs, and the initial fair value of the success fee combined with the stated interest resulted in an effective interest rate for the WAB loan of 8.49% for the year ended December 31, 2020. The final payment fee, debt issuance costs and the initial fair value of the success fee were accreted/amortized to interest expense using the effective interest method over the life of the loan.

PWB Term Loan

In August 2020, the Company entered into a new loan agreement (the "PWB Loan Agreement") with a different lender, Pacific Western Bank, and received a loan in the principal amount of $2,000 (the "PWB Term Loan") that bears interest on the outstanding daily balance at a rate equal to the greater of: (a) 0.50% above the variable rate of interest announced by the lender as its “prime rate” then in effect; or (b) 4.50%. The PWB Loan Agreement created a first priority security interest with respect to substantially all assets of the Company, including proceeds of intellectual property, but expressly excluding intellectual property itself.

The proceeds of the PWB Term Loan were used to pay off the entire amount of the Company's indebtedness on the WAB loan, which amounted to $1,512. Pursuant to the PWB Loan Agreement, the remainder of the PWB Term Loan proceeds may be used for general corporate purposes, which totaled $480, net of debt discounts and issuance costs.

The Company is required to pay accrued interest on the current loan on the 13th day of each month through and including August 13, 2023. The principal balance of the PWB Term Loan matures on August 13, 2023, at which time all unpaid principal and accrued and unpaid interest shall be due and payable in full. The interest rate of the PWB Term Loan is subject to increase in the event of late payments and after occurrence of and during the continuation of an event of default. Upon maturity, all unpaid principal and accrued and unpaid interest shall be due and payable in full. The Company may elect to prepay the PWB Term Loan at any time, in whole or in part, without penalty or premium.

The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain unrestricted cash and cash equivalents in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of June 30, 2021. On June 30, 2021, with cash on hand of $45,938, the Company was compliant with this liquidity covenant and all other covenants.

The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest rate of 4.70% for the three and six months ended June 30, 2021. The debt issuance costs will be amortized to interest expense using the effective interest method over the life of the loan.

The following table presents scheduled principal payments of the Company’s PWB term loan as of June 30, 2021:
18

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
PeriodAmount
Remainder of 2021 - 2022$ 
20232,000 
Total principal payments2,000 
Less debt discount and issuance cost9 
Note payable, net$1,991 
 
Current portion$ 
Long-term portion1,991 
Note payable, net$1,991 

Paycheck Protection Program Loan

On April 20, 2020, the Company received an unsecured loan in the principal amount of $1,086 under the Paycheck Protection Program (the “PPP”) administered by the U.S. Small Business Administration (the "SBA"), pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), or the PPP loan. The PPP loan bore interest at 1.00% per annum, and matured two years after the date of initial disbursement. The terms of the PPP loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on June 5, 2020. The PPP loan was used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments and interest payments on other debt obligation that were incurred before February 15, 2020. Under the terms of the CARES Act and the PPP Flexibility Act, the Company could apply for and be granted forgiveness for all or a portion of loan granted under the PPP loan, with such forgiveness to be determined, subject to limitations (including where employees of the Company have been terminated and not re-hired by a certain date), based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness were also subject to further requirements in regulations and guidelines adopted by the SBA. As of December 31, 2020, the PPP loan was included in Notes payable, net on the condensed consolidated balance sheets.

On June 28, 2021, the Company received notification from the SBA that the Company’s Forgiveness Application of the PPP loan and accrued interest, totaling $1,099, was approved in full, and the Company had no further obligations related to the PPP loan. Accordingly, the Company recorded a gain on the forgiveness of the PPP loan as gain on forgiveness of note payable on the condensed consolidated statement of operations.


9.    Lease Obligations

The Company maintains a five-year operating lease agreement for its headquarters and manufacturing facility in Richmond, California, or the Richmond Lease, which expires in May 2022, with no further options to extend or terminate. The lease includes non-lease components (i.e. common area maintenance costs) that are paid separately from rent based on actual costs incurred. In June 2020, the Company entered into an amendment to the Richmond Lease to make a one-time payment of $300 to cover its remaining lease obligations for the remainder of 2020, resulting in a $48 abatement and a lease payment deferral of $79 to be paid in equal monthly installments in 2021.

The Company's five-year operating lease agreement for its sales office in Hamburg, Germany expires in July 2022. The Company has an option to extend the lease for another five-year term.
 
The Company’s future lease payments as of June 30, 2021 are as follows, which are presented as lease liabilities on the Company’s condensed consolidated balance sheets:
19

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
PeriodOperating Leases
Remainder of 2021$301 
2022235 
Total lease payments536 
Less: imputed interest(22)
Present value of lease liabilities$514 
Weighted-average remaining lease term (in years)0.94
Weighted-average discount rate10.5 %

Lease expense under the Company’s operating leases was $132 and $135 for the three months ended June 30, 2021 and 2020, respectively, and $265 and $273 for the six months ended June 30, 2021 and 2020, respectively.

Practical Expedients

Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes the lease expense for such leases on a straight-line basis over the lease term.


10.    Capitalization and Equity Structure

Reverse Stock Split

After the close of the stock market on March 24, 2020, the Company effected a 1-for-15 reverse split of its common stock (the "Reverse Stock Split"). As a result, all common stock share amounts included in this filing have been retroactively reduced by a factor of fifteen, rounded up to the nearest whole share, and all common stock per share amounts have been increased by a factor of fifteen, with the exception of the Company's common stock par value and the Company's authorized shares. Amounts affected include common stock outstanding, restricted stock units, common stock underlying stock options and warrants.

Summary
 
The Company’s authorized capital stock at June 30, 2021 consisted of 141,429 shares of common stock and 10,000 shares of preferred stock. As of June 30, 2021 and December 31, 2020, there were 12,655 and 8,349, respectively, shares of common stock issued and outstanding and no shares of preferred stock issued and outstanding.

Common Stock

February 2021 Offering

In February 2021, the Company entered into an amended and restated underwriting agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), to sell 3,902 shares of the Company's common stock for a public price of $10.25 per share, for gross proceeds of $40,000 (the "February 2021 Offering"). The Company received net proceeds of $36,504 from the February 2021 Offering after deducting underwriting discounts, commissions and estimated offering expenses. Pursuant to the Underwriting Agreement, the Company issued, to certain designees of Wainwright, five year warrants (the “2021 Warrants”) to purchase shares of Common Stock in an amount equal to 7.0% of the aggregate number of shares sold in the February 2021 Offering, or 273 shares, at an exercise price of $12.81 per share.

At the Market Offering

In October 2020, the Company entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), under which the Company may issue and sell shares of its common stock, from time to time, to or through the Agent. The Company may offer and sell shares having an aggregate offering price of up to $7,500 under
20

Table of Contents

Ekso Bionics Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
($ and share amounts in thousands, except per share amounts)
(Unaudited)
the registration statement and prospectus supplement filed with the SEC related to such offering. Under the ATM Agreement, shares of the Company's common stock may not be sold for a price lower than $6.75 per share. During the six months ended June 30, 2021, the Company sold 78 shares of common stock at an average price per share of $10.72 for proceeds of $791, net of commission and issuance costs, under the ATM Agreement. The Company did not sell any shares under the ATM agreement during the three months ended June 30, 2021. As of June 30, 2021, the Company has $6,668 available for future offerings under the prospectus filed with respect to the ATM Agreement.

Warrants
 
Warrant shares outstanding as of December 31, 2020 and June 30, 2021 were as follows:  
SourceExercise
Price
Term
(Years)
December 31, 2020IssuedExercisedJune 30, 2021
2021 Warrants$12.81 5 273  273 
June 2020 Investor Warrants$5.18 5.5